alg-1001
Peptideexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01482871)
Timeline
Indications
Mechanism of action
- Fibronectin receptor betaANTAGONIST
ITGB1 antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- alg-1001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02153476 | Phase 2 | Feb 1, 2014 | Allegro Ophthalmics, LLC |
| NCT01749891 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2012 | Allegro Ophthalmics, LLC, APEC Hospital Mexico City |
| NCT01482871 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | Allegro Ophthalmics, LLC, University of Colorado, Denver |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allegro Ophthalmics, LLC | For profit | 3 | 3 | 1 | 2011 |
| APEC Hospital Mexico City | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1